BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/23/2024 4:13:00 AM | Browse: 320 | Download: 1215
 |
Received |
|
2023-11-20 02:15 |
|
Peer-Review Started |
|
2023-11-20 02:15 |
|
First Decision by Editorial Office Director |
|
2023-12-05 01:34 |
|
Return for Revision |
|
2023-12-05 01:34 |
|
Revised |
|
2023-12-13 14:45 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2024-01-02 02:50 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-01-02 06:45 |
|
Articles in Press |
|
2024-01-02 06:45 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-01-13 12:57 |
|
Publish the Manuscript Online |
|
2024-01-23 04:13 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Clinical and Translational Research |
| Article Title |
Gene signatures to therapeutics: Assessing the potential of ivermectin against t(4;14) multiple myeloma
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Yang Song, Hao-Jun Zhang, Xia Song, Jie Geng, Hong-Yi Li, Li-Zhong Zhang, Bo Yang and Xue-Chun Lu |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Key Research and Development Program of China |
2021YFC2701704 |
|
| Corresponding Author |
Xue-Chun Lu, PhD, Chief Doctor, Professor, Research Scientist, Department of Hematology, the Second Medical Center, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing 100853, China. luxuechun@301hospital.com.cn |
| Key Words |
Multiple myeloma; Functional enrichment analysis; Molecular docking simulation; Gene expression profiling; Therapeutic target; Ivermectin |
| Core Tip |
Multiple myeloma is a hematological malignancy with a significant impact on public health, and the t(4;14) subtype is particularly aggressive and resistant to existing treatments. Our study addresses the urgent need for new therapeutic approaches by employing a comprehensive approach that includes bioinformatics analysis, molecular docking, and experimental validation. We identified ten key genes associated with t(4;14) multiple myeloma (MM), shedding light on the molecular basis of this subtype. We explored the potential of ivermectin to assess whether it may be “repurposed” as a therapeutic agent for t(4;14) MM. Our findings indicate that ivermectin not only inhibits MM cell growth but also induces apoptosis via the nuclear factor-κB signaling pathway. |
| Publish Date |
2024-01-23 04:13 |
| Citation |
Song Y, Zhang HJ, Song X, Geng J, Li HY, Zhang LZ, Yang B, Lu XC. Gene signatures to therapeutics: Assessing the potential of ivermectin against t(4;14) multiple myeloma. World J Clin Oncol 2024; 15(1): 115-129 |
| URL |
https://www.wjgnet.com/2218-4333/full/v15/i1/115.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v15.i1.115 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
